A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Identifier
1698-304-007
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Plain Language Summary
Available Language(s): English
Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
  • Study Drug
  • Bimatoprost SR
  • LUMIGAN
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

    Study Locations

    Location
    Status
    Location
    Trinity Research Group /ID# 232749
    Dothan, Alabama, United States, 36301
    Status
    Not applicable
    Location
    The Eye Research Foundation /ID# 232694
    Newport Beach, California, United States, 92663-3637
    Status
    Not applicable
    Location
    Coastal Research Associates /ID# 232798
    Roswell, Georgia, United States, 30076
    Status
    Not applicable
    Location
    James D Branch MD /ID# 232718
    Winston-Salem, North Carolina, United States, 27101
    Status
    Not applicable
    Location
    Scott and Christie and Associates /ID# 232747
    Cranberry Township, Pennsylvania, United States, 16066
    Status
    Not applicable
    Location
    Keystone Research LTD /ID# 232665
    Austin, Texas, United States, 78731-4203
    Status
    Not applicable